Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Robotic surgery: The beginning and the journey so far.

The National medical journal of India·2026
Same author

Geospatial correlation of industrial plastics emissions with bladder and kidney cancer burden in Ohio.

Urologic oncology·2026
Same author

Development and validation of a digital pathology artificial intelligence (DPAI)-derived risk score predicting Gleason grade group reclassification for patients who are candidates for active surveillance.

Future oncology (London, England)·2026
Same author

New CPT codes for prostate biopsy improve alignment of reimbursement with evidence-based practice.

Urologic oncology·2026
Same author

Aberrant GATA3 reactivity in a clear cell renal cell carcinoma with clear cell papillary renal cell tumor-like features: a case report.

Virchows Archiv : an international journal of pathology·2026
Same author

International Society of Urological Pathology Consensus on Cancer Precursor Lesions: Working Group 3 Preneoplastic and Precursor Lesions of the Kidney.

The American journal of surgical pathology·2026
Same journal

Patient-Reported Symptom Burden Among Thyroid Cancer Survivors: Retrospective Cohort Study.

JCO clinical cancer informatics·2026
Same journal

Rule-Based Algorithm to Identify Recurrent Non-Hodgkin Lymphoma in Electronic Health Data.

JCO clinical cancer informatics·2026
Same journal

Bayesian Methods for Subgroup Efficacy and Safety: Application to Japanese Patients in JAVELIN Renal 101.

JCO clinical cancer informatics·2026
Same journal

Effect of a Multidimensional Digital Health Intervention on Quality of Life in Breast Cancer Survivors: A Randomized Controlled Trial.

JCO clinical cancer informatics·2026
Same journal

Can Small Open-Source Language Models With Retrieval-Augmented Generation Match GPT-4 Performance in Breast Cancer Clinical Decision Support?

JCO clinical cancer informatics·2026
Same journal

Machine Learning Algorithm for the Detection of Tumor Microsatellite Instability Based on Multiomics Biomarkers.

JCO clinical cancer informatics·2026
See all related articles

Related Experiment Video

Updated: Sep 19, 2025

Detection and Isolation of Cancer in Prostate Biopsies Using Stimulated Raman Histology and Artificial Intelligence
08:05

Detection and Isolation of Cancer in Prostate Biopsies Using Stimulated Raman Histology and Artificial Intelligence

Published on: June 10, 2025

675

Artificial Intelligence-Based Digital Histologic Classifier for Prostate Cancer Risk Stratification: Independent

Magdalena Fay1, Ross S Liao2, Zaeem M Lone2

  • 1Cleveland Clinic Lerner College of Medicine, Cleveland, OH.

JCO Clinical Cancer Informatics
|June 18, 2025
PubMed
Summary
This summary is machine-generated.

Artificial intelligence accurately predicts prostate cancer outcomes. The PATHOMIQ_PRAD test shows clinical validity in identifying high-risk patients after surgery, aiding treatment decisions.

More Related Videos

Introduction of an Integrated Pathology Image Management, Artificial Intelligence, and Reporting System
05:33

Introduction of an Integrated Pathology Image Management, Artificial Intelligence, and Reporting System

Published on: July 11, 2025

275
Microarray-based Identification of Individual HERV Loci Expression: Application to Biomarker Discovery in Prostate Cancer
13:19

Microarray-based Identification of Individual HERV Loci Expression: Application to Biomarker Discovery in Prostate Cancer

Published on: November 2, 2013

16.7K

Related Experiment Videos

Last Updated: Sep 19, 2025

Detection and Isolation of Cancer in Prostate Biopsies Using Stimulated Raman Histology and Artificial Intelligence
08:05

Detection and Isolation of Cancer in Prostate Biopsies Using Stimulated Raman Histology and Artificial Intelligence

Published on: June 10, 2025

675
Introduction of an Integrated Pathology Image Management, Artificial Intelligence, and Reporting System
05:33

Introduction of an Integrated Pathology Image Management, Artificial Intelligence, and Reporting System

Published on: July 11, 2025

275
Microarray-based Identification of Individual HERV Loci Expression: Application to Biomarker Discovery in Prostate Cancer
13:19

Microarray-based Identification of Individual HERV Loci Expression: Application to Biomarker Discovery in Prostate Cancer

Published on: November 2, 2013

16.7K

Area of Science:

  • Oncology
  • Digital Pathology
  • Artificial Intelligence

Background:

  • Artificial intelligence (AI) tools analyze digitized whole-slide images (WSIs) of prostate cancer (CaP) to predict patient outcomes.
  • Evaluating the clinical validity of AI-driven prognostic tests is crucial for their integration into clinical practice.

Purpose of the Study:

  • To assess the clinical validity of the AI-enabled prognostic test, PATHOMIQ_PRAD.
  • To evaluate PATHOMIQ_PRAD's performance in a clinical cohort from the Cleveland Clinic for prostate cancer risk stratification.

Main Methods:

  • Retrospective analysis of 344 prostatectomy patients (2009-2022) without adjuvant therapy.
  • PATHOMIQ_PRAD scores were used to stratify patients into high-risk and low-risk categories based on thresholds for biochemical recurrence and distant metastasis.
  • Comparison with Decipher genomic testing for prognostic accuracy.

Main Results:

  • PATHOMIQ_PRAD scores significantly correlated with biochemical recurrence-free survival (P <.001) and metastasis-free survival (P <.001).
  • High PATHOMIQ_PRAD scores (>0.55) were strongly associated with distant metastasis (HR, 10.10; P = .0284), even with low event rates.
  • The AI test demonstrated comparable or superior performance to Decipher in predicting outcomes.

Conclusions:

  • PATHOMIQ_PRAD is independently validated as a reliable predictor of clinical risk in post-prostatectomy prostate cancer patients.
  • The findings support prospective evaluation of PATHOMIQ_PRAD for risk stratification and guiding adjuvant or salvage therapy selection.